Crinetics PharmaceuticalsCRNX
CRNX
About: Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
Employees: 437
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
21% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 73
2.02% more ownership
Funds ownership: 107.48% [Q4 2024] → 109.5% (+2.02%) [Q1 2025]
8% less funds holding
Funds holding: 245 [Q4 2024] → 225 (-20) [Q1 2025]
33% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 55
33% less capital invested
Capital invested by funds: $5.1B [Q4 2024] → $3.42B (-$1.68B) [Q1 2025]
36% less funds holding in top 10
Funds holding in top 10: 14 [Q4 2024] → 9 (-5) [Q1 2025]
74% less call options, than puts
Call options by funds: $1.4M | Put options by funds: $5.45M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$60
89%
upside
Avg. target
$60
89%
upside
High target
$60
89%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Stifel Alex Thompson | 89%upside $60 | Buy Initiated | 25 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
4 days ago
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 74,000 shares of its common stock and granted an aggregate of 48,850 restricted stock unit (“RSU”) awards to 20 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
3 weeks ago
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY.
Neutral
GlobeNewsWire
1 month ago
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
New Analysis Shows Treatment with Investigational Paltusotine Resulted in Rapid and Durable IGF-1 Control in Surgically Naïve Acromegaly Patients
Neutral
GlobeNewsWire
1 month ago
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 152,475 shares of its common stock and granted an aggregate of 101,800 restricted stock unit (“RSU”) awards to 35 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
Seeking Alpha
1 month ago
Crinetics Pharmaceuticals, Inc (CRNX) Q1 2025 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX ) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder and Chief Executive Officer Isabel Kalofonos - Chief Commercial Officer Dana Pizzuti - Chief Medical and Development Officer Toby Schilke - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Jessica Fye - JPMorgan Gavin Clark-Gartner - Evercore ISI Francis DiGiovanna - TD Securities Cory Chobenville - LifeSci Capital Catherine Okoukoni - Citizens Alex Thompson - Stifel Maxwell Skor - Morgan Stanley Will Scheibler - Leerink Partners Anthea Theresa Li - Jefferies David Lebowitz - Citi Brian Skorney - Baird Douglas Tsao - H.C. Wainwright Andy Chen - Wolfe Research Catherine Novack - Jones Operator Welcome to the Crinetics Pharmaceuticals First Quarter 2025 Financial Results Conference Call.
Negative
Zacks Investment Research
1 month ago
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $0.93 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date
Neutral
GlobeNewsWire
2 months ago
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
SAN DIEGO, April 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2025 financial results on Thursday, May 8, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Neutral
GlobeNewsWire
2 months ago
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 124,950 shares of its common stock and granted an aggregate of 84,725 restricted stock unit (“RSU”) awards to 26 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Seeking Alpha
2 months ago
Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA
Crinetics Pharma's lead asset, Paltusotine, shows promising Phase 3 results for acromegaly, with a PDUFA date set for September 25, 2024. Paltusotine, an oral SST2 agonist, offers advantages over injectable somatostatin analogs, achieving high IGF-1 control rates in pretreated patients. Positive Phase 2 data for Paltusotine in carcinoid syndrome and Atumelnant in congenital adrenal hyperplasia highlight CRNX's expanding therapeutic potential.
Charts implemented using Lightweight Charts™